Holocene Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Holocene Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.45M	Buy	+180,849	New	+$5.82M	0.01%	388
2025 Q3	–	Sell	-3,053,340	Closed	-$51.2M	–	911
2025 Q2	$51.2M	Sell	3,053,340 -967,288	-24%	-$15.6M	0.12%	168
2025 Q1	$61.8M	Buy	4,020,628 +851,215	+27%	+$15.2M	0.18%	151
2024 Q4	$69.9M	Buy	3,169,413 +957,330	+43%	+$17.4M	0.22%	133
2024 Q3	$39.9M	Sell	2,212,083 -2,374,189	-52%	-$41.6M	0.16%	170
2024 Q2	$74.5M	Sell	4,586,272 -376,184	-8%	-$5.79M	0.31%	97
2024 Q1	$70M	Sell	4,962,456 -295,739	-6%	-$3.73M	0.26%	126
2023 Q4	$54.9M	Buy	5,258,195 +135,422	+3%	+$1.26M	0.21%	142
2023 Q3	$52.3M	Buy	+5,122,773	New	+$47.7M	0.23%	136

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors's TEVA Position: Q1 2026 in Review

Holocene Advisors opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2026: 180,849 shares worth $5.45M. The stake represents 0.01% of the portfolio and ranks #388 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in TEVA as recently as Q2 2025.

Holocene Advisors first reported a position in TEVA in Q3 2023 and has held it in 9 quarters since. The position peaked at $74.5M in Q2 2024. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Holocene Advisors held 180,849 shares of Teva Pharmaceuticals worth $5.45M as of Q1 2026.
Teva Pharmaceuticals was a new Holocene Advisors position in Q1 2026.
Teva Pharmaceuticals made up 0.01% of Holocene Advisors's portfolio in Q1 2026, its #388 holding.
Holocene Advisors first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
Holocene Advisors's Teva Pharmaceuticals position peaked at $74.5M in Q2 2024.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.